IR Contacts

Shareholder Services

Investor FAQ
Information Request
E-mail Alerts
IR Contacts

Primary IR Contact

Mark Klausner
Managing Partner
Westwicke Partners
Office: (443) 213-0501
Mobile: (410) 627-2087
E-mail: IR@neuronetics.com

Shareholder Tools

View printer-friendly version
RSS Feeds
E-mail Alerts
View contacts

Indication

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

NeuroStar TMS Therapy is only available by prescription. A doctor can help decide if NeuroStar TMS Therapy is right for you.

Important Safety Information

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of NeuroStar TMS (<0.1% per patient).

TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant
Safety and Prescribing Information »

Our Commitment

Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.
Commitment to Compliance »

Social Links

To find out more about NeuroStar TMS Therapy® or where treatment is available near you, please provide your contact information and a Neuronetics customer service representative will contact you. The information you provide to us is subject to the Neuronetics Privacy Policy.

General Contact Information

Customer Service Center: 1-877-600-7555